The researchers used primary care records from The Health Improvement Network (UK) between from 1994 to 2010 of adults 18 to 89 years old, including 8,700 with psoriatic arthritis (PsA), 138,000 with psoriasis, nearly 42,000 experiencing rheumatoid arthritis (RA), and 82,000 controls experiencing none of the conditions.
Slightly more than half the study’s psoriatic arthritis and rheumatoid arthritis patients were prescribed a disease-modifying antirheumatic drug. At least 65 percent of patients with PsA and RA were prescribed non-steroidal anti-inflammatory drugs compared with 24 percent of those with psoriasis and 47 percent of controls.
The researchers looked at the rate of MACE in psoriatic arthritis patients, psoriasis, and rheumatoid arthritis after adjusting for CV risk factors. Psoriatic arthritis patients were 36 percent more likely than the control group to experience a heart attack, whether or not they were prescribed a DMARD.
Psoriasis, a chronic immune disease, affects 7.5 million people in the U.S., according to the National Psoriasis Foundation. The Centers for Disease Control and Prevention report that 10 to 20 percent of those with psoriasis develop psoriatic arthritis. Rheumatoid arthritis afflicts more than 1 million U.S. adults, the American College of Rheumatology reports.
“We expected the increased risk of heart disease in these patients,” said Alexis Ogdie, MD, MSCE, assistant professor of rheumatology and lead author of the study. “Previous studies link whole-body inflammation with premature plaque buildup in the arteries.”
Senior author Joel M. Gelfand, MD MSCE noted that a surprising finding was that the increased risk of MACE and CV mortality in patients with more severe psoriasis was similar in magnitude to patients with rheumatoid arthritis.
“This finding,” Gelfand said, “emphasizes the clinical significance of cardiovascular risk associated with more severe psoriasis.”
Earlier studies linked psoriasis and rheumatoid arthritis to heart disease, but little was known about a link between psoriatic arthritis cases and heart disease. Gelfand and Ogdie are currently conducting clinical trials to determine if treatments used for psoriasis, psoriatic arthritis, and rheumatoid arthritis improve aortic vascular inflammation associated with these conditions (http://clinicaltrials.gov/show/NCT01553058).
Other Penn co-authors of the study include Kevin Haynes, Samantha Maliha, Yihui Jiang, Steven Kimmel, Sean Hennessy, David J Margolis, and Joel M. Gelfand.
The study was supported by the American College of Rheumatology, R01HL089744, K24AR064310. Data from The Health Improvement Network is supported by the Clinical and Translational Science Award at the University of Pennsylvania (8UL1TR000003 from the National Center for Research Resources). Additional funding came from the American College of Rheumatology Research and Education Foundation, NIH K23AR063764, and R01AG025152. This work was completed independent of the funders.
Disclosure: Gelfand is a consultant to Amgen, Abbott, Centocor, Celgene, Novartis, Eli Lily and Pfizer and has received honoraria. He has received grants from Amgen, Abbott, Pfizer, Novartis, Eli Lily and Genentech. Haynes and Hennessy are supported by sponsored research agreement between the University of Pennsylvania and Astra Zeneca and Bristol Myers Squibb. Hennessy has consulted for Bristol-Myers Squibb, AstraZeneca and Bayer Healthcare, and has received institutional support for pharmacoepidemiology training from Pfizer.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation’s first medical school) and the University of Pennsylvania Health System, which together form a $4.3 billion enterprise.
The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 17 years, according to U.S. News & World Report‘s survey of research-oriented medical schools. The School is consistently among the nation’s top recipients of funding from the National Institutes of Health, with $392 million awarded in the 2013 fiscal year.
The University of Pennsylvania Health System’s patient care facilities include: The Hospital of the University of Pennsylvania — recognized as one of the nation’s top “Honor Roll” hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; Chester County Hospital; Penn Wissahickon Hospice; and Pennsylvania Hospital — the nation’s first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Chestnut Hill Hospital and Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2013, Penn Medicine provided $814 million to benefit our community.